$1.5 Billion Valuation Signals a Shift in Venture Capital Focus
$230 million. That’s the size of the Series C funding round closed this week by Science Corporation, a brain-computer interface (BCI) startup founded by Max Hodak, formerly of Neuralink. While venture capital firms have largely concentrated on generative AI over the past 18 months – pouring $28.3 billion into the sector in the first half of 2024 alone, according to PitchBook data – this investment demonstrates a significant, and potentially predictive, recalibration towards tangible hardware solutions in biotech. Follow the money: the substantial valuation of $1.5 billion assigned to Science Corp. isn’t simply about future potential; it’s a vote of confidence in a near-term product launch and a recognition that the “AI winter” narrative may be overstated, particularly when applied to applications beyond software.
Drawn from TechCrunch.
From Pixium Vision’s Assets to a Potential Market First
Science Corp.’s strategy isn’t about reinventing the wheel, but rather accelerating a pre-existing innovation. The company acquired the assets of PRIMA, a retinal implant developed by French firm Pixium Vision in 2024. This acquisition, coupled with subsequent refinement and clinical trials, positions Science Corp. to potentially become the first BCI company to bring a product to market. This is a critical distinction. Many BCI ventures, including Neuralink, remain focused on long-term, ambitious goals like full brain-machine interfaces. Science Corp., however, is targeting a specific, addressable market – restoring functional vision to patients with advanced macular degeneration – with a device that has already demonstrated promising results. The 80% success rate in trials involving 47 patients, where participants regained the ability to read letters, numbers, and words, is a statistically significant outcome that surpasses previous attempts in the field.
Regulatory Pathways and the German Advantage
The timeline for commercialization hinges on regulatory approval, and Science Corp. is prioritizing the European Union. A CE mark application has been submitted, with an anticipated approval by mid-2026. This strategic focus on Europe isn’t accidental. Germany has emerged as a favorable launch market due to its established pathways for granting early access to novel medical technologies. This contrasts sharply with the more protracted and complex regulatory landscape in the United States, where discussions with the FDA are described as “ongoing.” This divergence highlights a key tension: while the U.S. represents a larger potential market, navigating its regulatory hurdles will likely take considerably longer, potentially ceding first-mover advantage to Science Corp. in Europe. The company’s decision to prioritize Germany isn’t simply about speed; it’s a calculated risk mitigation strategy.
Beyond Vision: A Diversified Portfolio of Neural Interfaces and Organ Preservation
The $230 million infusion isn’t solely earmarked for the PRIMA implant. Science Corp. is simultaneously pursuing a broader research portfolio, including a “biohybrid neural interface program” focused on growing engineered neurons directly onto brain circuits. This represents a longer-term, higher-risk, but potentially transformative approach to BCI technology. Furthermore, the company has launched Vessel, a new business line dedicated to organ preservation. Vessel aims to develop miniaturized perfusion technology to extend the viability of organs during transport, potentially revolutionizing transplant logistics and reducing organ waste. This diversification is crucial. While PRIMA offers a near-term revenue stream, the biohybrid interface and Vessel represent bets on future growth and demonstrate a commitment to tackling significant challenges in healthcare. The total funding now stands at $490 million, supporting a team of 150 employees, indicating a substantial operational capacity.
What This Means for Your Wallet
The Science Corp. funding round isn’t directly impacting consumer wallets today, but it signals a potential shift in healthcare costs down the line. If PRIMA successfully gains market traction, it could offer a viable alternative to managing advanced macular degeneration, potentially reducing the long-term financial burden associated with vision loss. However, the initial cost of the implant and associated procedures will likely be substantial, raising questions about accessibility and insurance coverage. Investors, and ultimately consumers, should watch closely for the pricing model Science Corp. adopts upon launch in Germany. Will it be positioned as a premium treatment available only to those with significant financial resources, or will the company prioritize broader access through partnerships with healthcare systems and insurance providers? The answer to that question will determine whether this technological breakthrough translates into a genuine improvement in quality of life for a wider population.
